Can Chemotherapy Cause Voice Hoarseness?

Chemotherapy can cause hoarseness, and it does so through more than one pathway. Some drugs damage the nerves that control the vocal cords, others dry out or inflame the tissues lining the larynx, and a few newer targeted therapies cause swelling in the airway that changes how the voice sounds. The effect is generally underappreciated by clinicians and patients alike, partly because voice changes get overshadowed by more life-threatening side effects during cancer treatment. But for someone going through chemotherapy who suddenly notices their voice sounds different, the connection is real and worth understanding.

How Chemotherapy Drugs Can Damage Vocal Cord Nerves

The most direct way chemotherapy causes hoarseness is by injuring the nerves that move the vocal cords. Several classes of chemotherapy drugs are known to cause peripheral neuropathy, meaning damage to nerves outside the brain and spinal cord. Vinca alkaloids, taxanes, and platinum-based agents are the main culprits. Most chemotherapy-related nerve damage is sensory, producing numbness and tingling in the hands and feet. But motor neuropathy, where the nerves that control muscle movement are affected, can also occur, and when it hits the nerves supplying the larynx, the result is vocal cord paralysis or weakness.¹

The vocal cords are controlled by the recurrent laryngeal nerve, a branch of the vagus nerve that takes a long looping path through the chest before reaching the larynx. That long route makes it vulnerable. When chemotherapy agents cause neuropathy along this nerve, one or both vocal cords may stop moving properly. If they cannot close fully during speech, the voice becomes breathy, weak, or hoarse. Chemotherapy-induced vocal fold motion impairment was first reported in the medical literature back in 1971, with vincristine being the drug most commonly linked to vocal cord palsy.¹

In one documented case, a patient receiving carboplatin and paclitaxel developed laryngeal palsy. Testing with laryngeal electromyography showed reduced nerve recruitment during phonation and signs of ongoing nerve injury, consistent with a neuropathic process rather than a structural problem in the larynx itself.² That case is a reminder that while most chemotherapy-related voice changes resolve, some do not.

Which Drugs Are Most Commonly Involved

Vincristine has the longest track record for causing vocal cord paralysis, but it is far from the only agent. Platinum-based drugs like cisplatin, carboplatin, and oxaliplatin have all been reported to cause voice changes, as have taxanes like paclitaxel. These drugs are among the most widely used in cancer treatment, appearing in regimens for head and neck cancers, lung cancer, ovarian cancer, colorectal cancer, and many others.¹

Oxaliplatin deserves special mention because its voice effects have been studied a bit more systematically than most. In one series of 81 consecutive patients receiving oxaliplatin-based chemotherapy, about 16% developed dysphonia. The onset was acute, the severity was mild to moderate, and all patients recovered relatively quickly.³ That 16% figure is striking because it suggests the problem is not as rare as case-report-level coverage would imply. Oxaliplatin is infamous for causing a distinctive cold-triggered nerve sensitivity in the hands and throat, so voice changes during treatment may get lumped in with that broader neuropathy picture rather than flagged as a separate issue.

Beyond traditional chemotherapy, anti-angiogenic drugs like bevacizumab have also been linked to hoarseness. In one reported case, a patient with ovarian cancer developed intermittent voice changes after starting bevacizumab, with periods where her voice became so soft it was inaudible. The connection between anti-angiogenic agents and dysphonia has appeared in large clinical trials, but clinicians are often unaware of it because it is so rarely discussed as a side effect.⁴

How Long Voice Changes Typically Last

One of the first questions patients ask is whether the hoarseness is permanent. The reassuring news is that in most cases, it is not. Chemotherapy-induced vocal cord palsy is usually bilateral, tends to appear during treatment, and often reverses once the responsible drug is stopped. The duration is highly variable, though. Across reported cases, symptom duration has ranged from as little as seven days to as long as 420 days, with an average around 106 days.¹

The oxaliplatin data paints a somewhat more optimistic picture for that particular drug. The voice changes in those patients were described as self-limiting and non-permanent, with rapid recovery.³ But the carboplatin-paclitaxel case mentioned earlier resulted in irreversible laryngeal palsy, so blanket reassurance would be misleading.² The outcome depends on the drug, the dose, how long the patient was exposed, and individual susceptibility. A key point for patients: if you develop hoarseness during chemotherapy, mention it to your oncologist. In some cases, recognizing the cause early and adjusting treatment can prevent further nerve damage.

When Chemotherapy Is Combined with Radiation

Many cancer treatment plans pair chemotherapy with radiation therapy, especially for head and neck cancers. When radiation targets areas near the larynx, the combination introduces a whole additional set of voice-damaging mechanisms that go beyond what chemotherapy alone would cause. Radiation can dry out the laryngeal mucosa, cause muscle atrophy and fibrosis in the vocal cord tissue, and trigger inflammation including hyperemia and erythema. Research has shown that radiation shrinks and damages the glands within the larynx, reducing the size and number of the cells that produce mucus and serous fluid. The result is less lubrication of the vocal folds, which makes them stiffer and less able to vibrate smoothly during speech.⁵

This means that for someone receiving chemoradiation, the voice effects can come from two directions at once: chemotherapy may damage the nerves controlling the vocal cords while radiation damages the tissue the cords are made of. Disentangling which treatment is responsible for which symptom is not always possible in clinical practice, and for the patient, the distinction matters less than the fact that their voice has changed and they want to know what can be done about it.

The fibrosis that radiation produces tends to be permanent to some degree, which is why voice changes after chemoradiation can be more persistent than those caused by chemotherapy alone. Patients treated for early glottic (voice box) cancer with radiation, for instance, may deal with long-term voice quality changes even after the cancer is cured.

Newer Immunotherapies and Voice Problems

Immune checkpoint inhibitors, a class of immunotherapy drugs that has transformed cancer treatment in recent years, have their own way of causing voice changes. These drugs work by unleashing the immune system to attack cancer cells, but sometimes the immune system also attacks healthy tissue. When that inflammation targets the upper airway, it can cause supraglottitis, or swelling of the structures just above the vocal cords.

In a reported case series, two patients developed significant supraglottitis while on checkpoint inhibitors. One was a 62-year-old man receiving nivolumab and relatlimab for melanoma, who developed hoarseness and difficulty swallowing. Examination showed significant airway swelling, mucous secretions, and inflammation. The other was a 76-year-old man being treated with pembrolizumab for bladder cancer, who noticed hoarseness and throat discomfort about four months into treatment. His examination also revealed diffuse supraglottic swelling.⁶

The mechanism here is different from the nerve damage that traditional chemotherapy causes. Checkpoint inhibitor-related inflammation is an immune-mediated reaction, and it can affect virtually any organ. The larynx is simply one more potential target. Treatment usually involves corticosteroids to tamp down the immune response, and in severe cases the immunotherapy drug may need to be paused or stopped. For patients on these drugs, hoarseness or a sore throat that persists for more than a few days warrants a call to the care team, because airway swelling can progress.

Infections That Can Complicate the Picture

Chemotherapy suppresses the immune system, and that opens the door to infections that can cause or worsen hoarseness independently of any direct drug toxicity. Laryngeal candidiasis, a fungal infection of the voice box, is one such complication. In immunocompromised patients, candida can colonize the larynx and produce progressive hoarseness that may mimic more serious conditions. One reported case involved a 79-year-old immunocompromised man who experienced 17 months of worsening hoarseness that initially raised concern for laryngeal cancer but turned out to be candida infection.⁷

This matters because a cancer patient on chemotherapy who develops hoarseness faces a wide differential diagnosis. The hoarseness could be from the chemotherapy itself, from radiation if they are receiving it, from an infection like candida, from gastroesophageal reflux worsened by treatment-related nausea, or from tumor progression. Assuming it is “just a side effect” without investigation can delay the identification of treatable causes like infection or, in the worst case, miss cancer recurrence affecting the airway. Dysphonia is the most common presenting symptom of chemotherapy-induced vocal cord palsy, but stridor, or noisy breathing, is present in roughly 40% of those cases, which signals a more serious degree of airway compromise.¹

Why Voice Changes During Chemotherapy Are Underreported

Dysphonia as a chemotherapy side effect does not get the attention it deserves, partly because it is not life-threatening and partly because clinical trials have historically not looked for it closely. Bevacizumab is a good example. Voice changes have appeared in the data from major trials of this drug, yet the finding gets buried in supplementary adverse-event tables rather than highlighted in the main results. Clinicians are often unaware that anti-angiogenic agents can affect the voice.⁴

From the patient’s side, the reluctance to report is understandable. When you are dealing with nausea, fatigue, neuropathy in your hands and feet, and the existential weight of a cancer diagnosis, a slightly hoarse voice may not seem worth mentioning at your next appointment. And when patients do mention it, the symptom may be chalked up to general debility, dehydration, or something unrelated to treatment. The oxaliplatin data suggests that if you actively look for dysphonia, you find it in a substantial minority of patients; if you wait for patients to complain, you may miss it entirely.³

This underreporting has practical consequences. If a drug’s voice-related side effects are not well characterized, patients are not counseled to expect them, oncologists do not recognize them when they appear, and the side effect does not factor into treatment decisions where an alternative regimen might spare the voice. For people whose livelihoods depend on their voice, like teachers, singers, or call center workers, that information gap is more than academic.

Voice Therapy and Rehabilitation After Treatment

For patients left with persistent voice changes after chemoradiation, voice therapy with a speech-language pathologist can help. A study examining voice therapy in patients treated with radiation for early glottic cancer found that therapy improved outcomes across multiple measures. Patients in the therapy group showed improvement on self-reported voice handicap scores, clinician ratings of voice quality, and objective acoustic measurements. Specific improvements included reduced vocal fry and better scores on jitter and harmonics-to-noise ratio, both of which reflect smoother, more regular vocal fold vibration.⁸

Voice therapy for post-cancer patients typically involves exercises to improve breath support, reduce strain on the vocal cords, and adapt speaking habits to accommodate whatever structural or nerve changes treatment has caused. The exercises are not dramatically different from those used for other voice disorders, but the context is unique: these patients may be dealing with dry mouth, swallowing difficulties, reduced sensation in the throat, and the psychological burden of a cancer experience all at once.

For chemotherapy-induced vocal cord palsy specifically, the approach depends on whether the paralysis is expected to recover. If the nerve damage is likely temporary, the strategy may involve watchful waiting with supportive therapy. If recovery stalls or the palsy appears permanent, surgical options like vocal fold injection or medialization procedures can bring a paralyzed cord closer to the midline, allowing the functioning cord to meet it during speech. These interventions do not restore nerve function but can substantially improve voice quality and reduce the effort of speaking.

The Emotional Weight of Losing Your Voice During Cancer

Voice changes during cancer treatment affect more than communication logistics. Research on patients with laryngeal cancer has found that impairment to speech, swallowing, and breathing produces substantial psychological distress and measurably reduced quality of life. The degree of impact varies depending on the treatment received, with long-term deficits particularly noted in the domains of voice and emotional well-being.⁹

Even for patients whose cancer does not directly involve the larynx, chemotherapy-induced voice changes can be isolating. Hoarseness makes phone conversations exhausting, social interaction feels effortful, and the voice change can serve as a constant, audible reminder of illness at a time when many patients are trying to maintain normalcy. Patients sometimes describe feeling like they have lost a part of their identity. These effects are worth acknowledging because they often go unaddressed in oncology settings focused primarily on tumor response and survival. Asking about voice changes during follow-up appointments, and connecting patients with speech-language pathologists when appropriate, can make a meaningful difference in someone’s experience of treatment and recovery.

1
PubMed Central. Vocal Cord Palsy Post Chemoradiation in Head and Neck Cancer: Challenges After Cure
2
Otolaryngology Case Reports. Irreversible laryngeal palsy: An induced complication of carboplatin 450mg/m2 and paclitaxel 250mg/m2 – Case report
3
PubMed. Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy
4
PubMed. Bevacizumab-induced dysphonia: A case report with brief review of literature
5
PubMed Central. Effects of chemoradiotherapy on voice and swallowing
6
PubMed. Immune Checkpoint Inhibitor Induced Supraglottitis: A Case Series
7
PubMed Central. Candida laryngitis appearing as carcinoma
8
PubMed Central. Effects of chemoradiotherapy on voice and swallowing – Section: Treatment of voice after chemoradiotherapy
9
PubMed Central. Psychological Distress and Quality of Life in Patients with Laryngeal Cancer: A Review